LTC2291080I2 - Sfingozino fosfato receptorių nauji moduliatoriai - Google Patents

Sfingozino fosfato receptorių nauji moduliatoriai

Info

Publication number
LTC2291080I2
LTC2291080I2 LTPA2020529C LTPA2020529C LTC2291080I2 LT C2291080 I2 LTC2291080 I2 LT C2291080I2 LT PA2020529 C LTPA2020529 C LT PA2020529C LT PA2020529 C LTPA2020529 C LT PA2020529C LT C2291080 I2 LTC2291080 I2 LT C2291080I2
Authority
LT
Lithuania
Prior art keywords
sfingosine
phosphate receptors
new modulators
modulators
new
Prior art date
Application number
LTPA2020529C
Other languages
English (en)
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of LTPA2020529I1 publication Critical patent/LTPA2020529I1/lt
Publication of LTC2291080I2 publication Critical patent/LTC2291080I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTPA2020529C 2008-05-14 2020-10-01 Sfingozino fosfato receptorių nauji moduliatoriai LTC2291080I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12760308P 2008-05-14 2008-05-14
PCT/US2009/003014 WO2009151529A1 (en) 2008-05-14 2009-05-14 Novel modulators of sphingosine phosphate receptors
US12/465,767 US8796318B2 (en) 2008-05-14 2009-05-14 Modulators of sphingosine phosphate receptors

Publications (2)

Publication Number Publication Date
LTPA2020529I1 LTPA2020529I1 (lt) 2020-10-26
LTC2291080I2 true LTC2291080I2 (lt) 2021-09-10

Family

ID=41416994

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2020529C LTC2291080I2 (lt) 2008-05-14 2020-10-01 Sfingozino fosfato receptorių nauji moduliatoriai

Country Status (20)

Country Link
US (8) US8796318B2 (lt)
EP (3) EP2291080B1 (lt)
JP (2) JP5837417B2 (lt)
AU (2) AU2009258242B2 (lt)
CY (2) CY1123338T1 (lt)
DK (1) DK2291080T3 (lt)
EA (1) EA021672B1 (lt)
ES (2) ES2549761T3 (lt)
FI (2) FI2291080T5 (lt)
HR (1) HRP20150982T1 (lt)
HU (2) HUE025984T2 (lt)
LT (1) LTC2291080I2 (lt)
MY (2) MY172105A (lt)
NL (1) NL301065I2 (lt)
NO (1) NO2020034I1 (lt)
NZ (1) NZ589617A (lt)
PL (2) PL2913326T3 (lt)
PT (2) PT2913326T (lt)
SI (1) SI2291080T1 (lt)
WO (1) WO2009151529A1 (lt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007292993B2 (en) 2006-09-07 2013-01-24 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
PT2195311E (pt) 2007-08-17 2011-05-25 Actelion Pharmaceuticals Ltd Derivados de piridina como moduladores do receptor s1p1/edg1
CA2700917A1 (en) 2007-11-01 2009-05-07 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
KR20100095593A (ko) 2007-12-10 2010-08-31 액테리온 파마슈티칼 리미티드 Ｓ１ｐ１/ｅｄｇ１의 작동약으로서 티오펜 유도체
JP5481395B2 (ja) 2008-03-07 2014-04-23 アクテリオン ファーマシューティカルズ リミテッド 新規なアミノメチルベンゼン誘導体
AU2009258242B2 (en) 2008-05-14 2015-07-16 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
HUE043090T2 (hu) 2008-06-09 2019-08-28 Univ Muenchen Ludwig Maximilians Gyógyszerek fehérjék aggregálódásának gátlására olyan betegségeknél, amelyek fehérje-aggregálódással és/vagy neurodegeneratív megbetegedésekkel függnek össze
US20100010053A1 (en) * 2008-06-20 2010-01-14 Jose Luis Castro Pineiro Compounds
KR20190004843A (ko) 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
JP5726737B2 (ja) 2008-08-27 2015-06-03 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2010085584A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
SI2454255T1 (sl) 2009-07-16 2014-01-31 Actelion Pharmaceuticals Ltd. Derivati piridin-4-ila kot agonisti s1p1/edg1
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
RS61829B1 (sr) * 2009-11-13 2021-06-30 Receptos Llc Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze
RS57070B1 (sr) * 2009-11-13 2018-06-29 Celgene Int Ii Sarl Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza
AU2015202660B2 (en) * 2009-11-13 2016-10-27 Receptos Llc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
AU2010319982B2 (en) * 2009-11-13 2016-02-04 Receptos Llc Selective heterocyclic sphingosine 1 phosphate receptor modulators
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
CA2789480A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2390252A1 (en) * 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
WO2012040532A1 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
KR101869120B1 (ko) 2011-01-19 2018-06-19 이도르시아 파마슈티컬스 리미티드 2-메톡시-피리딘-4-일 유도체
US8865754B2 (en) 2011-03-03 2014-10-21 Proteotech Inc. Compounds for the treatment of neurodegenerative diseases
CN102718726A (zh) * 2011-03-31 2012-10-10 上海铂力生物科技有限公司 作为免疫调节剂的(z)-5-苯亚甲基噻唑啉-4-酮衍生物
US9481659B2 (en) 2011-05-13 2016-11-01 Celgene International Ii Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
CA2894281C (en) 2012-12-20 2021-04-20 Inception 2, Inc. Triazolone compounds and uses thereof
PT2958913T (pt) 2013-02-20 2018-12-03 Lg Chemical Ltd Agonistas de recetores de esfingosina-1-fosfato, métodos para a sua preparação e composições farmacêuticas que os contêm como agente ativo
MX363545B (es) * 2013-03-15 2019-03-27 Idorsia Pharmaceuticals Ltd Derivados piridin-4-ilo.
EP3041826A4 (en) 2013-09-06 2017-02-15 Inception 2, Inc. Triazolone compounds and uses thereof
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
AU2015281799B2 (en) * 2014-06-26 2019-11-28 Central Adelaide Local Health Network Incorporated Enzyme interacting agents
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
AU2016246398A1 (en) 2015-04-06 2017-10-26 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
ES2770348T3 (es) 2015-05-20 2020-07-01 Idorsia Pharmaceuticals Ltd Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
ES3022204T3 (en) 2016-06-14 2025-05-28 Receptos Llc Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
WO2018033149A1 (zh) 2016-08-19 2018-02-22 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
CN109640982A (zh) 2016-09-14 2019-04-16 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
EP3518922B1 (en) 2016-09-29 2026-02-11 Receptos LLC Compounds and methods for treating lupus
WO2018136893A1 (en) 2017-01-23 2018-07-26 Naqi Logics, Llc Apparatus, methods, and systems for using imagined direction to define actions, functions, or execution
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US10981900B2 (en) * 2017-02-28 2021-04-20 Medshine Discovery Inc. Spiro compound and use thereof
WO2018211323A1 (en) * 2017-05-17 2018-11-22 Oppilan Pharma Ltd. Hetercyclic compounds for the treatment of disease
US11117876B2 (en) 2017-08-31 2021-09-14 Receptos Llc Crystalline form of ozanimod hydrochloride, and processes for preparation thereof
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
EP3847158A1 (en) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
WO2020152718A1 (en) 2019-01-25 2020-07-30 Mylan Laboratories Limited Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile
CN114008034A (zh) * 2019-04-26 2022-02-01 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
WO2021026479A1 (en) * 2019-08-07 2021-02-11 Stamford, Andrew Small molecule inhibitors of s1p2 receptor and uses thereof
EP4076448A4 (en) 2019-12-20 2024-03-27 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
KR20220158743A (ko) * 2020-03-27 2022-12-01 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절제
EP4126828A1 (en) * 2020-03-27 2023-02-08 Receptos Llc Sphingosine 1 phosphate receptor modulators
WO2021195396A1 (en) * 2020-03-27 2021-09-30 Receptos Llc Sphingosine 1 phosphate receptor modulators
WO2021207051A1 (en) * 2020-04-06 2021-10-14 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
US20230233532A1 (en) * 2020-06-26 2023-07-27 The Penn State Research Foundation Sphingosine-1-phosphate receptor 1 agonist and liposomal formulations thereof
CA3191164A1 (en) * 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
EP4333841A1 (en) 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride
WO2024117172A1 (ja) 2022-11-30 2024-06-06 花王株式会社 痒みの予防又は改善剤
WO2024246174A1 (en) 2023-05-31 2024-12-05 Química Sintética, S.A. Amorphous and crystalline form of ozanimod hydrochloride
CN119320366B (zh) * 2023-07-17 2025-11-18 中国医学科学院药物研究所 取代萘甲基噁二唑-苯胺类化合物及其用途
US11905265B1 (en) * 2023-10-13 2024-02-20 King Faisal University 3,4-dimethoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2ylthio)acetoxy)benzimidamide as an antimicrobial compound
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
ATE249455T1 (de) 1998-01-23 2003-09-15 Sankyo Co Spiropiperidin-derivate
DE10240818A1 (de) 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
CA2509218C (en) 2002-12-20 2010-09-07 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
CN100441185C (zh) 2003-04-30 2008-12-10 麦克弗罗斯特加拿大有限公司 8-(3-联芳基)苯基喹啉磷酸二酯酶-4抑制剂
WO2004110351A2 (en) * 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
AU2004277947A1 (en) 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
CN1894225A (zh) 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
WO2005058845A2 (en) * 2003-12-19 2005-06-30 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DK1650186T3 (da) 2004-10-22 2008-10-13 Sun Pharmaceutical Ind Ltd Nye dicarboxylsyrederivater
JP2008531546A (ja) 2005-02-22 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス
EP1893591A1 (en) 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
CN101346372B (zh) 2005-12-23 2011-09-28 弗·哈夫曼-拉罗切有限公司 芳基-异*唑-4-基-*二唑衍生物
TWI382984B (zh) * 2006-04-03 2013-01-21 Astellas Pharma Inc 雜環化合物
US20080015193A1 (en) * 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
US20080009534A1 (en) 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
MX2009003129A (es) 2006-09-29 2009-04-06 Novartis Ag Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras.
JP2010510250A (ja) * 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ
CN101562977A (zh) 2006-12-15 2009-10-21 艾博特公司 新的二唑化合物
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
US20090188269A1 (en) 2008-01-25 2009-07-30 Henkel Corporation High pressure connection systems and methods for their manufacture
DK2913326T3 (da) 2008-05-14 2020-08-17 Scripps Research Inst Hidtil ukendte modulatorer af sphingosinphosphatreceptorer
AU2009258242B2 (en) 2008-05-14 2015-07-16 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors

Also Published As

Publication number Publication date
DK2291080T3 (en) 2015-12-07
US9975863B2 (en) 2018-05-22
US8530503B2 (en) 2013-09-10
AU2009258242A1 (en) 2009-12-17
NZ589617A (en) 2012-06-29
EA201001785A1 (ru) 2011-10-31
JP2011523412A (ja) 2011-08-11
PT2291080E (pt) 2015-10-30
FI2291080T5 (fi) 2023-11-06
US20120329840A1 (en) 2012-12-27
NO2020034I1 (no) 2020-09-29
US20150057307A1 (en) 2015-02-26
JP5837417B2 (ja) 2015-12-24
PL2291080T3 (pl) 2015-12-31
AU2015213309B2 (en) 2016-10-13
AU2015213309A1 (en) 2015-09-03
FI2291080T3 (lt) 2015-10-15
US20180009770A1 (en) 2018-01-11
HUE025984T2 (hu) 2016-05-30
MY156381A (en) 2016-02-15
EP2291080A1 (en) 2011-03-09
US20190084947A1 (en) 2019-03-21
US9382217B2 (en) 2016-07-05
US8481573B2 (en) 2013-07-09
US10544136B2 (en) 2020-01-28
MY172105A (en) 2019-11-14
SI2291080T1 (sl) 2015-11-30
EP2913326B1 (en) 2020-07-15
PT2913326T (pt) 2020-08-24
US20100010001A1 (en) 2010-01-14
CY2020033I1 (el) 2020-11-25
AU2009258242B2 (en) 2015-07-16
ES2813368T3 (es) 2021-03-23
NL301065I2 (nl) 2020-10-28
US20120329838A1 (en) 2012-12-27
EP2291080A4 (en) 2013-09-11
EP2913326A1 (en) 2015-09-02
CY2020033I2 (el) 2021-01-27
EP2291080B1 (en) 2015-08-19
JP2016041736A (ja) 2016-03-31
US20120329839A1 (en) 2012-12-27
US20170050941A1 (en) 2017-02-23
US8466183B2 (en) 2013-06-18
HUS2000038I1 (hu) 2020-10-28
HRP20150982T1 (hr) 2015-10-23
EP3782991A1 (en) 2021-02-24
US8796318B2 (en) 2014-08-05
WO2009151529A9 (en) 2010-04-08
ES2549761T3 (es) 2015-11-02
CY1123338T1 (el) 2020-11-25
LTPA2020529I1 (lt) 2020-10-26
EA021672B1 (ru) 2015-08-31
FIC20200037I1 (fi) 2020-09-24
WO2009151529A1 (en) 2009-12-17
PL2913326T3 (pl) 2020-11-16
NL301065I1 (lt) 2020-09-30

Similar Documents

Publication Publication Date Title
LTC2291080I2 (lt) Sfingozino fosfato receptorių nauji moduliatoriai
DK2364314T3 (da) Modulatorer af toll-lignende receptorer
EP2326631A4 (en) MIF MODULATORS
EP2259678A4 (en) PROTEIN KINASE MODULATORS
PT2376533T (pt) Formulação de anticorpos
PT2496567T (pt) Novos moduladores de quinase benzopiran
BRPI0908269A2 (pt) aplicador
DK2297100T3 (da) Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
EP2344446A4 (en) S1P RECEPTOR MODULATORS
PT2260053E (pt) Análogos de oxitocina
EP2512245A4 (en) POSITIVE ALLOSTERIC PYRIDOCHINOLICIDIDINE M1 RECEPTOR MODULATORS
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
DK2913326T3 (da) Hidtil ukendte modulatorer af sphingosinphosphatreceptorer
EP2178371A4 (en) HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS
DK2271634T3 (da) Modulatorer af dopamin-neurotransmission
CU23884B1 (es) Derivados de dibenzotiazepina
EP2277578A4 (en) NEBULIZER
EP2139489A4 (en) Mineralocorticoid receptor modulators
EP2229167A4 (en) MINERALCORTICOIDREZEPTORMODULATOREN
DK2240433T3 (da) Polymorfe former af oseltamivir-phosphat
EP2242554A4 (en) FLOW DISTRIBUTION
EE05511B1 (et) „siaplikaatori adapter
EE200800059A (et) K„siaplikaatori kinnitus
DOP2006000291A (es) 3-aminociclopentacarboxamidas como moduladores de receptores de quimioquinas
AP2859A (en) Modulators of toll-like receptors